Affordable Access

Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial.

Authors
  • Bennett-Guerrero, E
  • Sorohan, J G
  • Gurevich, M L
  • Kazanjian, P E
  • Levy, R R
  • Barberá, A V
  • White, W D
  • Slaughter, T F
  • Sladen, R N
  • Smith, P K
  • Newman, M F
Type
Published Article
Journal
Anesthesiology
Publication Date
Dec 01, 1997
Volume
87
Issue
6
Pages
1373–1380
Identifiers
PMID: 9416723
Source
Medline
License
Unknown

Abstract

Aprotinin was more effective than epsilon-aminocaproic acid at decreasing bleeding and platelet transfusions. Epsilon-aminocaproic acid, however, was the more cost-effective therapy over a broad range of estimates for bleeding-related costs in patients undergoing repeated cardiac surgery. A cost-benefit analysis using the lower cost of half-dose aprotinin ($540) still resulted in a significant cost advantage using epsilon-aminocaproic therapy (P = 0.022).

Report this publication

Statistics

Seen <100 times